Skip to main
OBIO

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Holdings Inc. is strategically positioned for growth, demonstrated by a significant increase in its eligible patient pool, expanding by over 24-fold due to a protocol update, which supports the target enrollment of 500 patients by mid-2026. Despite a rise in both SG&A and R&D expenses, reflecting a commitment to advancing product development and commercialization, the company continues to focus on high-impact technologies that have shown clinical promise, particularly in treating hypertension and cardiovascular conditions. The success of Orchestra BioMed's innovative products will largely depend on the capabilities of its commercial partners to penetrate target markets and drive sales, which could enhance the financial outlook for the company as these collaborations unfold.

Bears say

Orchestra BioMed Holdings Inc. has incurred operating losses since its inception, raising concerns about its long-term profitability. The potential for delayed and costly clinical trials, along with the uncertainty surrounding the safety and efficacy of its product candidates, further exacerbates its financial outlook. Additionally, the risk that key intellectual property may not adequately protect its products could hinder its competitive position in the biomedical market.

OBIO has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 5 analysts, OBIO has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.